• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Blood Pressure Lowing Pharmacotherapy Have a Positive Effect into Old Age?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • It is unclear how much older patients benefit from blood pressure lowering pharmacological intervention, particularly when their blood pressure is not substantially increased 
  • The Blood Pressure Lowering Treatment Trialists’ Collaboration (Lancet, 2021) compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline 

METHODS: 

  • Systematic review and meta-analysis 
    • Individual participant-level data from randomized controlled trials 
  • Study inclusion criteria 
    • Pharmacological blood-pressure-lowering vs placebo or other classes of blood-pressure-lowering medications 
    • More vs less intensive treatment strategies 
    • Exclusion: Previous history of heart failure 
  • Study design 
    • Patients were categorized into  
      • Baseline age groups: <55 years, 55 to 64 years, 65 to 74 years, 75 to 84 years, and ≥85 years 
      • Blood pressure categories: In 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic 
  • Primary outcome 
    • Composite: Fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischemic heart disease 
    • Heart failure causing death or requiring hospital admission 

RESULTS: 

  • 358,707 participants | 51 randomized clinical trials 
    • Age range 21 to 105 years (median 65; IQR 59 to 75) 
      • Participants <55 years: 12.0% 
      • 55 to 64: 35.8% 
      • 65 to 74 years: 35.8% 
      • 75 to 84 years: 15.1% 
      • ≥85 years: 1.3% 
  • Hazard ratios (HR) for risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure (adjusted pinteraction=0.050) 
    • <55 years: HR 0.82 (95% CI, 0.76 to 0.88) 
    • 55 to 64 years: HR 0.91 (95% CI, 0.88 to 0.95) 
    • 65 to 74 years: HR 0.91 (95% CI, 0.88 to 0.95) 
    • 75 to 84 years: HR 0.91 (95% CI, 0.87 to 0.96) 
    • ≥85: HR 0.99 (95% CI, 0.87 to 1.12) 
  • Similar patterns of proportional risk reductions were observed per 3 mm Hg reduction in diastolic blood pressure 
  • Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups 

CONCLUSION: 

  • Pharmacological blood pressure reduction appears to have a sustained benefit into old age 
    • Risk reduction for major cardiovascular events did not vary by blood pressure levels at randomization, down to <120/70 mmHg 
  • The authors conclude that age-related blood-pressure thresholds should be removed from international guidelines 
  • The authors conclude 

…we found no evidence to substantiate the common approach of withholding antihypertensive treatment for older adults, in particular when their blood pressure is not highly elevated 

Therefore, pharmacological blood pressure reduction should be considered as an important treatment option for the prevention of cardiovascular events even in those aged 80 years or older and guidelines should be simplified to remove any differing blood pressure thresholds by age 

Learn More – Primary Sources: 

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Meta-Analysis: Does Baseline BP Impact Cardiovascular Risk When Lowering Systolic BP?
Cochrane Review 2021: Does Walking Reduce Blood Pressure and Heart Rate?
Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site